June 22 (Reuters) - Springworks Therapeutics Inc:
* BEIGENE AND SPRINGWORKS ANNOUNCE PRESENTATION OF PRECLINICAL DATA COMBINING RAF DIMER INHIBITOR LIFIRAFENIB WITH MEK INHIBITOR MIRDAMETINIB AND PROVIDE UPDATE ON ONGOING PHASE 1B/2 CLINICAL TRIAL
* SPRINGWORKS THERAPEUTICS - ONGOING PHASE 1B/2 CLINICAL TRIAL ON TRACK TO COMMENCE DOSE EXPANSION COHORTS IN KRAS MUTANT SOLID TUMORS BY 2020-END Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.